In August, the Brazilian vice-commissioner for patents, Julio Cesar Moreira, announced that INPI was implementing new rules in order to reduce the current backlog of patent applications, which averages eight years, to three years.
In August, the Brazilian vice-commissioner for patents, Julio Cesar Moreira, announced that the Brazilian Patent and Trademark Office (INPI) was implementing new rules in order to reduce the current backlog of patent applications, which averages eight years, to three years, and minimise delays in granting patents.
The most important rule is the creation of a priority line for pharmaceutical patents. However, the creation of a priority line for patents for medications considered vital for the Brazilian government’s Unified Health System (SUS), and mentioned by Moreira in order to reduce the average time for granting, was introduced in 2008.
Resolution #191 of 2008 established the guidelines for priority examination of patent applications before INPI. Article 4 of Resolution #191 of 2008 established a priority line of examination of pharmaceutical patent applications covering drugs purchased by the SUS: “Article 4: Will be examined as a priority, as requested by the Ministry of Health, patent applications related to drugs regularly acquired by SUS.”
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
INPI, pharmaceuticals, ANVISA, Takeda
